VCCC Alliance Breast Cancer Grand Round with Dr Dilanka De Silva

Universal Germline and Somatic Testing for All Newly Diagnosed Breast Cancer

09 Aug 2023

The current standard of care for breast cancer testing may not be enough. Are we missing pathogenic actionable germline variants? Unravel the mysteries of germline testing in breast cancer with Dr Dilanka De Silva, and hear new insights emerging from the ground-breaking MAGIC study.

The Mutational Assessment of newly diagnosed breast cancer using Germline and tumour genomics (MAGIC) study is the first of its kind in Australia to challenge the status quo of the existing standard of breast cancer care. It evaluates the prevalence of pathogenic germline variants in the Australian breast cancer population and the accuracy of its detection compared to current methods.

The implications of timely result delivery on clinical management, the psychosocial acceptability of universal germline testing, and the potential effects of combined germline and somatic information on patient management are all integral aspects of this transformative study.

Aim: to present new insights gained from The Mutational Assessment of newly diagnosed breast cancer using Germline and tumour genomics (MAGIC) study. 

Learning objective:  In this session, you will gain insights into if we are missing pathogenic actionable germline variants as the MAGIC study says yes, by more than 50%.